Pixium Vision SA is a France-based company that specializes in sensory neuromodulation. The Company is focused on the development of implantable medical devices for the treatment of blindness caused by degeneration of photoreceptor cells in the retina. The Company develops two Vision Restoration Systems (VRS) platforms, including IRIS and PRIMA. The Company’s implant technology replaces the signal processing functions in the retina by electrically stimulating the retinal cells, enabling them to transmit the stimulation signals to the brain’s visual cortex via the optic nerve, and its other systems initially enables patients with retinitis pigmentosa to partially recover their vision. The Company has collaboration with technology and academic institutions, including the Institut de la Vision (Paris), Universite Pierre et Marie Curie (Paris), Stanford University (the United States) and University of Ulm (Germany).